The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review [PDF]
Current Oncology, 2021 Background: The role of denosumab in patients with resectable giant cell tumour of bone remains unclear. We asked the following research question: for patients (aged ≥ 12 years) with resectable giant cell tumour of bone, what are the benefits and harms ...
Abha Gupta +5 more
doaj +2 more sources
Giant cell tumour of bone in os sacrum of a prepubertal girl – Surgical and medical treatment with zoledronate and denosumab [PDF]
Bone Reports, 2023 A giant cell tumour of bone presented in the os sacrum of a prepubertal girl. Surgery with reconstruction was performed, but total resection was impossible.
Signe Sparre Beck-Nielsen +5 more
doaj +2 more sources
Vertebral giant cell tumour of bone in a domestic shorthair cat [PDF]
Journal of Feline Medicine and Surgery Open Reports, 2023 Case summary A 10-year-old male neutered domestic shorthair cat was presented with a 5-month history of progressive non-ambulatory paraparesis. Initial vertebral column radiographs revealed an L2–L3 expansile osteolytic lesion.
Jordina Caldero Carrete +3 more
doaj +2 more sources
The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone [PDF]
World Journal of Surgical Oncology, 2021 Background Denosumab (XgevaTM) is a fully human antibody to RANK-Ligand, an important signal mediator in the pathogenesis of giant cell tumour of bone (GCTB).
Wolfram Weschenfelder +2 more
doaj +2 more sources
Management and surveillance of metastatic giant cell tumour of bone [PDF]
Pathology and Oncology ResearchGiant cell tumour of bone (GCTB) is viewed as a benign, locally aggressive primary bone tumour with metastatic potential. Current management is surgery with bone curettage or resection and systemic therapy with denosumab.
David Fellows +8 more
doaj +2 more sources
Journal of Orthopaedic Translation, 2019 Background: Denosumab is gradually applied to refractory or unresectable giant cell tumour of the bone. Whether denosumab can effectively reduce the blood supply of tumour and bring benefit is worthy of study.
Xiaohui Niu +5 more
doaj +3 more sources
Utility of p63 in Giant Cell Lesions of Bone- A Case Series [PDF]
Journal of Clinical and Diagnostic Research, 2022 Giant cell lesions of bone include a relatively large group of biologically and morphologically diverse bone lesions which shows presence of numerous multinucleate osteoclast like giant cells.
Shima Kannadas +4 more
doaj +1 more source
Giant Cell Tumour of Soft Tissue in Neck: An Uncommon Tumour in an Uncommon Location [PDF]
Journal of Clinical and Diagnostic Research, 2015 Giant cell tumour of soft tissue is an extremely rare tumour. It is thought to be the soft tissue counterpart of giant cell tumours of the bone due to its histological and immunohistochemical resemblances.
Abhishek Bandyopadhyay +4 more
doaj +1 more source
Current status of bone cementing and bone grafting for giant cell tumour of bone: a systemic review. [PDF]
Ann R Coll Surg Engl, 2019 Vaishya R +3 more
europepmc +2 more sources
Aggressive Giant Cell Tumour of Talus with Pulmonary Metastasis-A Rare Presentation [PDF]
Journal of Clinical and Diagnostic Research, 2014 Giant cell tumour (GCT) is a primary benign neoplasm of bone. It is classically described as a locally invasive tumour that occurs close to the joint of a mature bone. It accounts for 5% of all skeletal tumours.
B Udaya Kumar +3 more
doaj +1 more source